Introduction
Streptococcus pyogenes is an important human Gram-positive pathogen that mainly causes throat and skin infections, such us pharyngitis, impetigo and cellulitis. Although the majority of streptococcal infections are superficial, some cases may progress into invasive and life threatening diseases with an extremely rapid progression, such as streptococcal septic shock and necrotizing fasciitis (1) . In order to infect the human host, S. pyogenes expresses a number of virulence factors that mediate adhesion to host tissues, enable dissemination of bacteria, and/or that modulate the immune response ( 2-4).
The streptococcal collagen-like surface proteins A and B (SclA and SclB), also known as Scl1 and Scl2, are two related proteins with a similar structure motif, including a Cterminal region that is attached to the cell wall-membrane (CWM) via a LPATG anchor. This is followed by a central region composed of a collagen-like domain (CL) with long segments of repeated GXY amino acids, a sequence considered a defining feature of collagens. Next to the CL domain, an amino terminal variable domain (V) is present located. In addition, SclA, but not SclB, contains a linker (L) region between the CWM and the CL domain. Both proteins are organized into a "lollipop-like" structure, where the CL domain forms a triple helical-stalk and the V domain folds into a globular head.
The genes encoding SclA and SclB are located at different sites of the bacterial chromosome and are differently regulated. While SclA is up-regulated by the Mga regulon, the transcription of SclB is down-regulated by the same protein (5-10).
Recently, we reported the binding of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) to the surface of a group A streptococci (M41 serotype) and its subsequent activation at the bacterial surface via plasmin and thrombin-thrombomodulin (11) . Furthermore, activation of TAFI on the surface of S. pyogenes evoked inflammatory reactions by modulating the kallikrein/kinin systems (12) . Identifying the molecular determinants of Scls-TAFI interaction may well offer possibilities for prevention of diseases caused by inflammatory reactions induced by S. pyogenes.
TAFI is a zinc-dependent procarboxypeptidase that is synthesized in the liver (13) . It is thereafter released into the bloodstream, where it circulates at a concentration in the range of 70-275 nM (14) . Cleavage of the TAFI zymogen by enzymes such as thrombin or plasmin results in the formation of activated TAFI (TAFIa), which attenuates fibrinolysis.
TAFIa prevents accelerated plasmin formation by removing C-terminal lysine residues from partially degraded fibrin that augment the efficacy of plasminogen activation.
Besides a function in fibrinolysis, TAFIa also plays a role in inflammatory processes by hydrolysis of bradykinin, osteopontin and the anaphylotoxins C3a and C5a (15) .
The present study was undertaken to 1) identify the TAFI binding site involved in the interaction with the SclA, SclB expressed by S. pyogenes and 2) establish the binding properties of TAFIa to SclA and SclB. Using synthetic TAFI peptides, we demonstrated that TAFI binds to both Scl proteins via residues G205 to D232. In addition, we determined that TAFIa is able to bind SclA and SclB but that it rapidly dissociates from the bacterial proteins. (P19) and in solid-phase binding assays, peptides were 95 % pure as determined by highpressure liquid chromatography analysis, and their identity was confirmed by mass spectrometry. Recombinant SclA and SclB from the S. pyogenes AP41 strain were produced and purified as described elsewhere (11) . TAFI was purified as previously described ( 16) . The rTAFI-IIYQ mutant, which harbours the Thr325 Ile, Thr329 Ile, His333Tyr and His335Gln mutations, and the active form of the mutant (rTAFIa-IIYQ) were generated and expressed as described previously ( 17, 18) . A polyclonal antibody specific for TAFI was obtained in rabbits as described elsewhere (19) . HRP (horseradish peroxidise)-labeled swine anti-rabbit immunoglobulin G (IgG) was purchased from Dako.
Matherials and methods

Proteins
SPR (Surface Plasmon Resonance) binding assays
All SPR measurements were performed at 25°C using a BIAcore 2000 biosensor System (GE Healthcare). Recombinant AP41 SclA and SclB were immobilized to a CM5 sensor chip using the amine coupling kit according to the supplier's recommendation (GE Healthcare). SclA and SclB were applied in 10 mM NaAc (pH 3. hour at 37ºC. Wells were washed as described above, and 100 nM TAFI in the presence or absence of P18, P19 or P29 (0 to 150 µM) diluted in blocking buffer was applied to the wells. The assay mixture was incubated for 1 hour at room temperature. Following the competition step, microtiter plates were washed three times, and 100 µl of anti-TAFI antibody was incubated in blocking buffer for 1 hour at room temperature. Next, the plates were washed three times and incubated with HRP-labeled swine anti-rabbit IgG diluted 1:5000 with blocking buffer. After four washes, the reactions were developed by the addition of 100 µl o-phenylenediamine (Sigma-Aldrich) substrate [8 
Results
Characterization of TAFI binding to SclA and SclB
We have previously shown that TAFI binds to SclA and SclB (11) . In the present study, we examined the TAFI region involved in SclA and SclB binding. These data imply that P18 and P19 have a similar binding region as TAFI for binding to SclA and SclB.
Binding analysis of TAFIa to SclA and SclB
Next we used SPR to investigate the binding characteristics of TAFIa to SclA and SclB.
Because TAFIa is a labile enzyme that is inactivated by a conformational change in a temperature-dependent way ( 16) we used a TAFI quadruple mutant, rTAFI-IIYQ, which has a 70-fold more stable active form (rTAFIa-IIYQ) than the wild type.
Both SclA and SclB were immobilized onto the sensor chip surface, and binding curves Fitting the SPR profiles to interaction models yielded kinetic and affinity information for the different TAFI-Scls interactions. The responses for rTAFI-IIYQ were well described by a 1:1 interaction model, however, the responses for rTAFIa-IIYQ were not. Instead, the profiles for the active form could be better described by a heterogeneous surface model, which assumed two or more different classes of binding sites. We found similar association rates of rTAFI-IIYQ and rTAFIa-IIYQ towards the bacterial proteins. In contrast, the dissociation curves for rTAFI-IIYQ and rTAFIa-IIYQ were different; rTAFIa-IIYQ presented a faster dissociation phase towards both SclA and SclB. to Asp232 is located distally from the TAFI catalytic site (►Fig.4) within helix α-4 and is surface exposed and does not interfere with the region known to influence TAFIa stability (Arg302, Arg320, Arg330, and Thr/Ile325) (20) (21) (22) , neither with the residues involved in substrate binding (Gly336, Tyr341, and Glu363) (23) .
Although different binding partners have been identified for TAFI, such as plasminogen and fibrinogen (24), the region described here as involved in SclA and SclB binding has not been shown to be overlapping with another TAFI-protein interaction.
We demonstrated that P18 and P19 have the potential to compete with TAFI for binding to the streptococcal proteins. TAFI binding to SclA was inhibited 55% and 76% by P18 and P19 respectively. In contrast, TAFI binding to SclB was inhibited 44% and 26% by P18 and P19 respectively. The partial contribution of P18 and P19 to inhibit TAFI-SclB interaction may be attributed to the fact that SclA and SclB contain different sizes of the variable region. In addition, it is likely that the recognition between the bacterial proteins and TAFI is dependent on the three-dimensional conformation of the protein, which is not optimally represented by the linear peptides.
Recent findings that the physiological activity of TAFIa is not inhibited by SclA or SclB (11) , and the ability of activated TAFI on the surface of S. pyogenes to evoke inflammatory reactions by modulating the kallikrein/kinin system (12), prompted us to investigate the TAFIa binding properties to SclA and SclB. Here we provide evidence that activated TAFI binds to SclA and SclB and, in contrast to the TAFI proenzyme, is rapidly dissociated from the bacterial proteins. It is tempting to speculate that this constitutes a mechanism whereby the bacteria attract TAFI to their surface and localize it there. After activation however, the activated TAFI can dissociate and act on substrates elsewhere. These findings suggested that the activation peptide may play a role in the TAFI binding to SclA and SclB. However, we found that the TAFI binding to SclA and SclB was mediated by a region within the TAFI catalytic domain. The crystal structure of TAFI showed that TAFIa stability is directly related to the dynamics of a 55-residue segment (residues 296-350) of the active site (17, 25) . Release of the activation peptide increases dynamic flap mobility and in time this leads to conformational changes that expose the cleavage site at Arg302. It cannot be ruled out that binding of TAFIa to SclA and SclB is influenced by the conformational change in TAFIa.
In summary, this study demonstrates that binding of TAFI to SclA and SclB can be inhibited by TAFI peptides. We have identified the region on TAFI, encompassing residues 205-232, that bind to the bacterial proteins. In addition, it was shown that TAFIa rapidly dissociates from SclA and SclB. A better understanding of the molecular mechanisms behind host/bacteria interactions has the potential to discover important targets in the human host and ultimately new therapeutic approaches for treatment of severe infectious diseases.
TAFI, thrombin-activatable fibrinolysis inhibitor; TAFIa, activated-thrombin activatable fibrinolysis inhibitor; SclA and SclB, streptococcal surface collagen-like proteins A and B; SPR, surface plasmon resonance. The one-letter code for amino acid residues is used for the sequence. The positions of the amino acids in TAFI protein are shown. 
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